Product Description
PHLDA2 Antibody | 22-077 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-152 of human PHLDA2 (NP_003302.1) .
Research Area: Apoptosis, Cancer, Cell Cycle
Tested Application: WB, IF
Application: WB: 1:500 - 1:2000
IF: 1:20 - 1:100
Specificiy: N/A
Positive Control 1: SW620
Positive Control 2: SKOV3
Positive Control 3: HeLa
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Observed: 20kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Concentration: N/A
Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.
Alternate Name: PHLDA2, pleckstrin homology-like domain, family A, member 2, TSSC3, IPL, BRW1C, BWR1C, HLDA2, PHLDA2, tumor suppressing subtransferable candidate 3, tumor-supressing STF cDNA 3, imprinted in placenta and liver, p17-Beckwith-Wiedemann region 1C, pleckstrin homology-like domain family A member 2, tumor suppressing subchromosomal transferable fragment cDNA 3
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene is located in a cluster of imprinted genes on chromosome 11p15.5, which is considered to be an important tumor suppressor gene region. Alterations in this region may be associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene has been shown to be imprinted, with preferential expression from the maternal allele in placenta and liver.